Klinker H - Search Results

1

Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin.

Berg T, von Wagner M, Nasser S, Sarrazin C, Heintges T, Gerlach T, Buggisch P, Goeser T, Rasenack J, Pape GR, Schmidt WE, Kallinowski B, Klinker H, Spengler U, Martus P, Alshuth U, Zeuzem S. Berg T, et al. Among authors: klinker h. Gastroenterology. 2006 Apr;130(4):1086-97. doi: 10.1053/j.gastro.2006.02.015. Gastroenterology. 2006. PMID: 16618403 Clinical Trial.

2

Individualized treatment strategy according to early viral kinetics in hepatitis C virus type 1-infected patients.

Berg T, Weich V, Teuber G, Klinker H, Möller B, Rasenack J, Hinrichsen H, Gerlach T, Spengler U, Buggisch P, Balk H, Zankel M, Neumann K, Sarrazin C, Zeuzem S. Berg T, et al. Among authors: klinker h. Hepatology. 2009 Aug;50(2):369-77. doi: 10.1002/hep.22991. Hepatology. 2009. PMID: 19575366 Clinical Trial.

3

Improved responses to pegylated interferon alfa-2b and ribavirin by individualizing treatment for 24-72 weeks.

Sarrazin C, Schwendy S, Möller B, Dikopoulos N, Buggisch P, Encke J, Teuber G, Goeser T, Thimme R, Klinker H, Boecher WO, Schulte-Frohlinde E, Prinzing R, Herrmann E, Zeuzem S, Berg T. Sarrazin C, et al. Among authors: klinker h. Gastroenterology. 2011 Nov;141(5):1656-64. doi: 10.1053/j.gastro.2011.07.019. Epub 2011 Jul 22. Gastroenterology. 2011. PMID: 21784046 Clinical Trial.

4

The determination of GGT is the most reliable predictor of nonresponsiveness to interferon-alpha based therapy in HCV type-1 infection.

Weich V, Herrmann E, Chung TL, Sarrazin C, Hinrichsen H, Buggisch P, Gerlach T, Klinker H, Spengler U, Bergk A, Zeuzem S, Berg T. Weich V, et al. Among authors: klinker h. J Gastroenterol. 2011 Dec;46(12):1427-36. doi: 10.1007/s00535-011-0458-y. Epub 2011 Sep 13. J Gastroenterol. 2011. PMID: 21912897

5

Prediction of minimal residual viremia in HCV type 1 infected patients receiving interferon-based therapy.

Knop V, Teuber G, Klinker H, Möller B, Rasenack J, Hinrichsen H, Gerlach T, Spengler U, Buggisch P, Neumann K, Sarrazin C, Zeuzem S, Berg T. Knop V, et al. Among authors: klinker h. Ann Hepatol. 2013 Mar-Apr;12(2):190-8. Ann Hepatol. 2013. PMID: 23396729 Free article.

6

Reduced dose and duration of peginterferon alfa-2b and weight-based ribavirin in patients with genotype 2 and 3 chronic hepatitis C.

Manns M, Zeuzem S, Sood A, Lurie Y, Cornberg M, Klinker H, Buggisch P, Rössle M, Hinrichsen H, Merican I, Ilan Y, Mauss S, Abu-Mouch S, Horban A, Müller TH, Welsch C, Chen R, Faruqi R, Pedicone LD, Wedemeyer H. Manns M, et al. Among authors: klinker h. J Hepatol. 2011 Sep;55(3):554-563. doi: 10.1016/j.jhep.2010.12.024. Epub 2011 Jan 13. J Hepatol. 2011. PMID: 21237227 Clinical Trial.

7

Importance of minimal residual viremia for relapse prediction in patients with chronic hepatitis C genotype 1 infection.

Wiegand J, Neumann K, Böhm S, Weich V, Teuber G, Klinker H, Möller B, Rasenack J, Hinrichsen H, Gerlach T, Spengler U, Buggisch P, Sarrazin C, Berg T. Wiegand J, et al. Among authors: klinker h. Clin Infect Dis. 2011 Dec;53(11):1111-4. doi: 10.1093/cid/cir670. Epub 2011 Oct 21. Clin Infect Dis. 2011. PMID: 22021919

8

Treatment of HCV genotype 2 with sofosbuvir and ribavirin results in lower sustained virological response rates in real life than expected from clinical trials.

Tacke F, Günther R, Buggisch P, Klinker H, Schober A, John C, Lutz T, Pfeiffer-Vornkahl H, Niederau C, Cornberg M, Sarrazin C, Mauss S. Tacke F, et al. Among authors: klinker h. Liver Int. 2017 Feb;37(2):205-211. doi: 10.1111/liv.13206. Epub 2016 Aug 10. Liver Int. 2017. PMID: 27428297

9

Real-world experience with daclatasvir plus sofosbuvir ± ribavirin for post-liver transplant HCV recurrence and severe liver disease.

Herzer K, Welzel TM, Spengler U, Hinrichsen H, Klinker H, Berg T, Ferenci P, Peck-Radosavljevic M, Inderson A, Zhao Y, Jimenez-Exposito MJ, Zeuzem S. Herzer K, et al. Among authors: klinker h. Transpl Int. 2017 Mar;30(3):243-255. doi: 10.1111/tri.12910. Transpl Int. 2017. PMID: 28012215 Free article.

10

Treatment of hepatitis C genotype 1 infection in Germany: effectiveness and safety of antiviral treatment in a real-world setting.

Höner Zu Siederdissen C, Buggisch P, Böker K, Schott E, Klinker H, Pathil A, Pfeiffer-Vornkahl H, Berg T, Sarrazin C, Hüppe D, Manns MP, Mauss S. Höner Zu Siederdissen C, et al. Among authors: klinker h. United European Gastroenterol J. 2018 Mar;6(2):213-224. doi: 10.1177/2050640617716607. Epub 2017 Jun 17. United European Gastroenterol J. 2018. PMID: 29511551 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

220 results

Search Page